ClinicalTrials.gg
CompletedNCT03137173Updated Sep 18, 2026Results posted

Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections

A Phase 3 interventional study of ceftobiprole medocaril and vancomycin+aztreonam in Acute Bacterial Skin and Skin Structure Infections, sponsored by Basilea Pharmaceutica. Completed at 34 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-18.

Sponsored by Basilea Pharmaceutica · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
679
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This was a randomized, double-blind, active-controlled, parallel-group, multicenter study in adult hospitalized patients to establish the safety and efficacy of ceftobiprole medocaril compared with vancomycin plus aztreonam in the treatment of acute bacterial skin and skin structure infections (ABSSSIs).

Read the detailed description

This was a randomized, double-blind, active-controlled, parallel-group, multicenter study in adult hospitalized patients with ABSSSIs. Randomization was stratified by study site and type of ABSSSI (with major cutaneous abscess comprising ≤ 30% of the Intent-to-Treat [ITT] population).

Primary endpoint for FDA: Early clinical response based on the percent reduction in lesion size at 48-72 hours compared to baseline in patients who did not receive rescue therapy and were alive, in the ITT population.

Primary endpoint for EMA: Investigator-assessed clinical success at the test-of-cure (TOC) visit 15-22 days after randomization, in the co-primary ITT and Clinically Evaluable (CE) populations.

02

Conditions studied

  • Acute Bacterial Skin and Skin Structure Infections
03

In context

Lead sponsor

Basilea Pharmaceutica is the lead sponsor of 60 studies on the registry; 7 are open to participants now.

Of its 22 completed or terminated interventional studies of FDA-regulated products, 15 (68%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, aged ≥18 years.
  2. Diagnosis of ABSSSI, meeting at least one of the definitions in (a) to (c) below. Local symptoms must have started within the 7 days prior to the Screening visit:

    1. Cellulitis/erysipelas, defined as a diffuse skin infection characterized by all of the following within 24 hours:

      • i. Rapidly spreading areas of erythema, edema, and/or induration with a minimum total lesion surface area of 75cm\^2
      • ii. No collection of pus apparent upon visual examination
      • iii. At least two of the following local signs of infection:

        • erythema
        • induration
        • localized warmth
        • pain or tenderness on palpation
        • swelling/edema
    2. Major cutaneous abscess, defined as infection characterized by a collection of pus within the dermis or deeper that is apparent upon visual examination before or after therapeutic intervention and is accompanied by all of the following within 24 hours:

      • i. Erythema, edema and/or induration with a minimum total lesion surface area of 75 cm\^2.
      • ii. At least two of the following local signs of infection:

        • fluctuance
        • incision and drainage required
        • purulent or seropurulent drainage
        • localized warmth
        • pain or tenderness on palpation
    3. Wound infection, defined as infection of any apparent break in the skin characterized by at least one of the following:

      • i. Superficial incision/surgical site infection meeting all of the following criteria:

        • involves only the skin or subcutaneous tissue around the incision (does not involve fascia).
        • occurs within 30 days of procedure.
        • purulent drainage (spontaneous or therapeutic) with surrounding erythema, edema and/ or induration with a minimum total lesion surface area of 75cm\^2.
      • ii. Post-traumatic wound (including penetrating trauma, e.g., needle, nail, knife, insect and spider bites) meeting the following criterion within 24 hours:

        • Purulent drainage (spontaneous or therapeutic) with surrounding erythema, edema and/or induration with a minimum total lesion surface area of 75cm\^2.
  3. At least one of the following regional or systemic signs of infection at the Screening visit:

    1. Lymph node tenderness and volume increase, or palpable lymph node proximal to the primary ABSSSI.
    2. Fever > 38 °C/100.4 °F measured orally, > 38.5 °C / 101.3 °F measured tympanically, > 37.5 °C / 99.5 °F measured by the axillary method, or > 39 °C / 102.2 °F measured rectally.
    3. White blood cell (WBC) count > 10.0 × 10\^9/L or \< 4.0 × 10\^9/L.
    4. > 10% immature neutrophils (band forms).
  4. Requirement for IV antibacterial treatment.
  5. Willing and able to adhere to study procedures (including prohibitions and restrictions) as specified in this protocol.
  6. Willing and able to remain hospitalized (in a hospital or equivalent medical confinement or clinical research unit) until completion of the early-clinical-response assessment for the primary endpoint.
  7. signed by the patient, or their legally acceptable representative if appropriate, indicating that they understand the purpose of, and procedures required for, the study, and are willing to participate.

Exclusion criteria

EXCLUSION CRITERIA

Patients meeting any one of the following:

  1. Use of any systemic antibacterial treatment within 14 days, or topical antibacterial administration on the primary lesion within 96 hours, before first infusion of study drug.

    Exception: Receipt of a single dose of a short acting (half-life ≤ 12 hours) antibacterial therapy (e.g., for surgical prophylaxis) within > 3 days before randomization (i.e., patients cannot have received any antibacterial treatment within 72 hours of randomization).

  2. to the administration of either of the study treatments, including known clinically-relevant to related antibacterial treatments (e.g., beta-lactam and glycopeptide antibiotics), or to metronidazole if required as adjunctive therapy.
  3. Participation in any other clinical study within the 30 days prior to randomization, or any prior participation in this study.
  4. The primary ABSSSI is an uncomplicated skin and skin structure infection, such as furuncles, minor abscesses (area of suppuration not surrounded by cellulitis/erysipelas), impetiginous lesions, superficial or limited cellulitis/erysipelas, or minor wound infections (e.g., stitch abscesses).
  5. The primary ABSSSI is due to, or associated with, any of the following:

    1. Diabetic foot infection, gangrene, or perianal abscess.
    2. Concomitant infection at another site (e.g., septic arthritis, endocarditis, osteomyelitis), not including a secondary ABSSSI lesion.
    3. Infected burns.
    4. Decubitus or chronic skin ulcer, or ischemic ulcer due to peripheral vascular disease (arterial or venous).
    5. Any evolving necrotizing process (e.g., necrotizing fasciitis).
    6. Infections at vascular catheter sites, or involving thrombophlebitis.
  6. The primary ABSSSI is associated with, or in close proximity to, a prosthetic device.
  7. Patients who are placed in a hyperbaric chamber as adjunctive therapy for the ABSSSI.
  8. Patients expected to require more than two surgical interventions in the operating room for the ABSSSI.
  9. Severe sepsis or septic shock.
  10. Significant or life-threatening condition (e.g., endocarditis, meningitis) that would confound, or interfere with, the assessment of the ABSSSI.
  11. Another severe, acute or chronic medical condition, psychiatric condition, or laboratory abnormality that may increase the risks associated with study participation or administration of the product, or may interfere with the interpretation of study results, and which, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
  12. Receiving treatment for active tuberculosis.
  13. \< 0.5 × 10\^9/L.
  14. Recent history of opportunistic infections (i.e., within 30 days) if the underlying cause of these infections is still active (e.g., leukemia, transplant, acquired immunodeficiency syndrome [AIDS]).
  15. Patients receiving systemic (> 40 mg per day prednisolone, or equivalent), or receiving drugs.
  16. Requirement for peritoneal dialysis, plasmapheresis, hemodialysis, venovenous dialysis, or other forms of renal filtration, or expected to require such treatment before the TOC visit.
  17. (ALT) or aspartate transaminase (AST) levels ≥ 8× the , OR severe hepatic disease with class C.
  18. Women who are pregnant or nursing.
  19. Women who are of and unwilling to use an acceptable method of during the study: female sterilization (bilateral tubal occlusion or oophorectomy, or hysterectomy) or male partner vasectomy; intrauterine device (IUD); combined (estrogen and progesterone containing) hormonal contraception (oral, vaginal ring, or transdermal patch) with an ethinylestradiol dose of at least 30 µg, plus use of male condoms (preferably with spermicides), female condoms, a female diaphragm or a cervical cap; or total sexual abstinence.

    Women are not considered to be of childbearing potential if they are either ≥ 1 year (where menopause is defined as at least 12 months of amenorrhea), or have a serum follicle stimulating hormone (FSH) measurement consistent with post-menopausal status according to local laboratory thresholds. An FSH measurement at Screening is to be obtained for post-menopausal females aged \< 50 years, or for those aged ≥ 50 years who have been post-menopausal for \< 2 years.

  20. Inability to start study-drug therapy within 24 hours of Screening.
  21. Patients with illicit drug use within 12 months of screening, including heroin, other opioids (unless prescribed for medical reasons unrelated to heroin substitution), cocaine / crack cocaine, and amphetamine or methamphetamine. Exception: Cannabis use.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
679 participants (actual)

Study arms

  • Experimental
    ceftobiprole medocaril

    Patients treated with ceftobiprole medocaril 500 mg q8h (with dose adjustment for renal impairment).

    Drug: ceftobiprole medocaril

  • Active comparator
    vancomycin+aztreonam

    Patients treated with vancomycin 1000 mg (or 15 mg/kg) q12h plus aztreonam 1000 mg q12h (both with dose adjustment for renal impairment).

    Drug: vancomycin+aztreonam

Interventions

  • ceftobiprole 500 mg was to be administered every 8 hours as a 2-hour IV infusion (with dose adjustment for renal impairment). The treatment duration was for a minimum of 5 days and a maximum of 10 days. Treatment could be extended up to 14 days if in the investigator's opinion this was required, and the extension was approved by the sponsor's medical monitor.

    Also known as: ceftobiprole

  • Drugvancomycin+aztreonam

    Drug pages: Vancomycin · Aztreonam

    Vancomycin 1000 mg (or 15 mg/kg) was to be administered every 12 hours (with dose adjustment for renal impairment) as 2-hour IV infusion. Vancomycin dose adjustment for morbidly obese and hypermetabolic patients was to be done according to local standard of care. When locally available, vancomycin trough testing (VTT) might have been used by the unblinded pharmacist or delegate to adjust the vancomycin dose. The treatment duration was for a minimum of 5 days and a maximum of 10 days. Treatment could be extended up to 14 days if in the investigator's opinion this was required, and the extension was approved by the sponsor's medical monitor. Aztreonam 1000 mg was to be administered as a 0.5-hour IV infusion every 12 hours. If CLCR was \< 30 mL/min (i.e., severe renal impairment), the aztreonam dosage regimen was to be adjusted. The requirement to continue aztreonam therapy beyond Day 3 was to be reassessed at the 72-hour study visit.

06

What researchers measure

Primary outcomes

  1. Early Clinical Response

    Comparison of early clinical response, including ≥ 20% reduction from baseline in the primary lesion area (based on ruler measurements), survival for ≥ 72 hours and no rescue therapy in the ITT population

    Time frame: 48-72 hours after start of study drug treatment

Secondary outcomes

  1. Investigator-assessed Clinical Success in the ITT Population

    Comparison of investigator-assessed clinical success (based on resolution of baseline signs and symptoms of the primary infection) in the ITT population

    Time frame: 15-22 days after randomization

  2. Investigator-assessed Clinical Success in the Clinically Evaluable (CE) Population

    Comparison of investigator-assessed clinical success (based on resolution of baseline signs and symptoms of the primary infection) in the clinically evaluable (CE) population

    Time frame: 15-22 days after randomization

07

Results

Posted May 18, 2020

Participant flow

Patients with an ABSSSI who received any systemic antibacterial treatment within 14 days, or topical antibacterial administration on the primary lesion within 96 hours, before first infusion of study drug were not allowed to enter the study. Hospitalization in a medical clinic was mandatory for the first 72 hours.

Participant flow — Overall Study
MilestoneCeftobiprole MedocarilVancomycin+Aztreonam
Started335344
Completed309308
Not completed2636
Withdrew: Withdrawal by subject813
Withdrew: Death13
Withdrew: Physician decision10
Withdrew: Lost to follow-up1318
Withdrew: Other reasons32

Outcome measures

PrimaryEarly Clinical Response

Comparison of early clinical response, including ≥ 20% reduction from baseline in the primary lesion area (based on ruler measurements), survival for ≥ 72 hours and no rescue therapy in the ITT population

Time frame:
48-72 hours after start of study drug treatment
Reported as:
Count of participants · Participants
Early Clinical Response
ParticipantsCeftobiprole MedocarilVancomycin+Aztreonam
Early Clinical Response306303
Statistical analysis
  • Ceftobiprole Medocaril vs Vancomycin+Aztreonam · Risk difference (rd): 3.3 · 95% CI -1.2 to 7.8
SecondaryInvestigator-assessed Clinical Success in the ITT Population

Comparison of investigator-assessed clinical success (based on resolution of baseline signs and symptoms of the primary infection) in the ITT population

Time frame:
15-22 days after randomization
Reported as:
Count of participants · Participants
Investigator-assessed Clinical Success in the ITT Population
ParticipantsCeftobiprole MedocarilVancomycin+Aztreonam
Investigator-assessed Clinical Success in the ITT Population302306
Statistical analysis
  • Ceftobiprole Medocaril vs Vancomycin+Aztreonam · Risk difference (rd): 1 · 95% CI -3.5 to 5.6
SecondaryInvestigator-assessed Clinical Success in the Clinically Evaluable (CE) Population

Comparison of investigator-assessed clinical success (based on resolution of baseline signs and symptoms of the primary infection) in the clinically evaluable (CE) population

Time frame:
15-22 days after randomization
Reported as:
Count of participants · Participants
Investigator-assessed Clinical Success in the Clinically Evaluable (CE) Population
ParticipantsCeftobiprole MedocarilVancomycin+Aztreonam
Investigator-assessed Clinical Success in the Clinically Evaluable (CE) Population277279
Statistical analysis
  • Ceftobiprole Medocaril vs Vancomycin+Aztreonam · Risk difference (rd): 2.7 · 95% CI -0.3 to 5.6

Adverse events

Collected over Up to 35 days after last treatment. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ceftobiprole Medocaril1/334 (0.3%)6/334 (1.8%)63/334 (18.9%)
Vancomycin+Aztreonam3/342 (0.9%)12/342 (3.5%)47/342 (13.7%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventCeftobiprole MedocarilVancomycin+Aztreonam
SKIN BACTERIAL INFECTIONINFECTIONS AND INFESTATIONS1/3343/342
CELLULITISINFECTIONS AND INFESTATIONS0/3342/342
PNEUMONIAINFECTIONS AND INFESTATIONS1/3340/342
ACCIDENTAL OVERDOSEINJURY, POISONING AND PROCEDURAL COMPLICATIONS1/3340/342
BRONCHIAL OBSTRUCTIONRESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS1/3340/342
PRURITUSSKIN AND SUBCUTANEOUS TISSUE DISORDERS1/3340/342
RASHSKIN AND SUBCUTANEOUS TISSUE DISORDERS1/3340/342
DEEP VEIN THROMBOSISVASCULAR DISORDERS1/3341/342
CARDIAC ARRESTCARDIAC DISORDERS0/3341/342
ABDOMINAL PAINGASTROINTESTINAL DISORDERS0/3341/342
Most frequent other events
Most frequent other events
EventCeftobiprole MedocarilVancomycin+Aztreonam
NauseaGastrointestinal disorders36/33420/342
HeadacheNervous system disorders19/33424/342
DiarrhoeaGastrointestinal disorders21/33416/342

Baseline characteristics

ITT population

Age, Categorical
Age, Categorical(Participants)Ceftobiprole MedocarilVancomycin+AztreonamTotal
<=18 years000
Between 18 and 65 years294292586
>=65 years415293
Sex: Female, Male
Sex: Female, Male(Participants)Ceftobiprole MedocarilVancomycin+AztreonamTotal
Female137143280
Male198201399
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Ceftobiprole MedocarilVancomycin+AztreonamTotal
White318330648
Black or African American7815
Asian011
American Indian or Alaska Native437
Native Hawaiian or other Pacific Islander101
Other527
Hispanic or Latino103115218
Region of Enrollment
Region of Enrollment(participants)Ceftobiprole MedocarilVancomycin+AztreonamTotal
Hungary213
United States203215418
Ukraine8280162
Bulgaria484896
Type of ABSSSI
Type of ABSSSI(Participants)Ceftobiprole MedocarilVancomycin+AztreonamTotal
Cellulitis/erysipelas112111223
Major cutaneous abscess9693189
Wound infection127140267
08

Study locations

34 sites
  • Physician Alliance Research Center
    Anaheim, California 92804, United States
  • Saint Joseph's Clinical Research
    Anaheim, California 92804, United States
  • eStudySite - Chula Vista - PPDS
    Chula Vista, California 91911, United States
  • Central Valley Research LLC
    Fresno, California 93721, United States
  • Marvel Clinical Research
    Huntington Beach, California 92647, United States
  • eStudySite - La Mesa - PPDS
    La Mesa, California 91942, United States
  • Omnibus Clinical Research
    La Palma, California 90623, United States
  • Alliance Research LLC
    Long Beach, California 90813, United States
  • Long Beach Clinical Trials
    Long Beach, California 90813, United States
  • Central Valley Research, LLC
    Modesto, California 95350, United States
  • Gonzalez MD and Aswad MD Health Services
    Coral Gables, Florida 33134, United States
  • L&C Professional Medical Research Institute
    Miami, Florida 33144, United States
  • Mercury Street Medical Group
    Butte, Montana 59701, United States
  • eStudySite - Las Vegas - PPDS
    Las Vegas, Nevada 89109, United States
  • Excel Clinical Research
    Las Vegas, Nevada 89109, United States
  • South Jersey Infectious Disease
    Somers Point, New Jersey 08244, United States
  • University Multiprofile Hospital for Active Treatment
    Pleven, 5800, Bulgaria
  • University Multiprofile Hospital for Active Treatment
    Plovdiv, 4004, Bulgaria
  • University Multiprofile Hospital for Active Treatment
    Rousse, 7002, Bulgaria
  • "University Multiprofile Hospital for Active Treatment and Emergency Medicine ""N. I. Pirogov"", Clinic of Purulent-Septic Surgery-"N.I. Pirogov""
    Sofia, 1606, Bulgaria
  • Kaposi Mor Teaching Hospital
    Kaposvár, 7400, Hungary
  • CRU Hungary Ltd.
    Miskolc, 3529, Hungary
  • University of SzegednAlbert Szent-Gyorgyi Clinical Center
    Szeged, 6720, Hungary
  • Csolnoky Ferenc Hospital
    Veszprém, 8200, Hungary
  • Dnipropetrovsk I.I. Mechnуkov Regional Clinical Hospital, Surgery Department #2
    Dnipro, 49005, Ukraine
  • Ivano-Frankivsk City Clinical Hospital Surgery 1
    Ivano-Frankivsk, 76008, Ukraine
  • Ivano-Frankivsk City Clinical Hospital General Surgery
    Ivano-Frankivsk, 76018, Ukraine
  • Kyiv City Clinical Hospital
    Kyiv, 03110, Ukraine
  • Public City Clinical Hospital of Emergency Medical Care
    Lviv, 79000, Ukraine
  • Lviv Regional Clinical Hospital
    Lviv, 79059, Ukraine
  • Central City Clinical Hospital
    Uzhhorod, 88000, Ukraine
  • Vinnytsia M.I. Pyrohov Regional Clinical Hospital
    Vinnytsia, 21018, Ukraine
  • Zaporizhia City Clinical Hospital of Urgent and Emergency Medical Care
    Zaporizhia, 69000, Ukraine
  • Central District Hospital
    Zhytomyr, 12430, Ukraine
09

References and documents

Publications

  • Welte T, Scheeren TW, Overcash JS, Saulay M, Engelhardt M, Hamed K. Efficacy and safety of ceftobiprole in patients aged 65 years or older: a post hoc analysis of three Phase III studies. Future Microbiol. 2021 May;16:543-555. doi: 10.2217/fmb-2021-0042. Epub 2021 May 7. PubMed 33960817 ↗
  • Overcash JS, Kim C, Keech R, Gumenchuk I, Ninov B, Gonzalez-Rojas Y, Waters M, Simeonov S, Engelhardt M, Saulay M, Ionescu D, Smart JI, Jones ME, Hamed KA. Ceftobiprole Compared With Vancomycin Plus Aztreonam in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Results of a Phase 3, Randomized, Double-blind Trial (TARGET). Clin Infect Dis. 2021 Oct 5;73(7):e1507-e1517. doi: 10.1093/cid/ciaa974. PubMed 32897367 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2018 to primary completion in Apr 2019, 14 months.

Results were first posted in May 2020, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2017
First posted
May 2, 2017
StartActual
Feb 19, 2018
Primary completionActual
Apr 22, 2019
CompletionActual
Apr 22, 2019
Results first posted
May 18, 2020
Last update
Sep 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03137173
Collaborators
Biomedical Advanced Research and Development Authority
Responsible party
Sponsor
First posted
May 2, 2017
Start date
Feb 19, 2018
Primary completion
Apr 22, 2019
Completion
Apr 22, 2019
Results posted
May 18, 2020
Last update
Sep 18, 2026

Study contacts

Marc Engelhardt, MD
study director · Basilea Pharmaceutica

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ceftobiprole medocaril

Start the discussion